Why Abzena?

We have over 20 years of experience in delivering solutions at each stage of the development lifecycle from early-stage research and discovery, through lead candidate selection, and onward into process development and GMP manufacture.

Unlike most other service providers, we can provide technical and scientific support that truly spans early-stage research through process development and GMP manufacturing under a single organization to better ensure that the TPP can be achieved. Our global scientific teams have extensive experience in overcoming some of the most challenging and complex biologic and bioconjugate programs, making us the perfect partner for novel and disruptive technologies that other CDMOs may shy away from.

Our experienced team is focused on getting it right from the start. We identify and address challenges early in drug design to better ensure downstream clinical and commercial success. We also have expertise in fixing and optimizing drugs in later stage development to rescue them from the drug development graveyard.

Our team is always seeking new ways to innovate and streamline development for our customers. Our extensive scientific capabilities and proprietary solutions like EpiScreen® 2.0, Composite Proteins™, Composite Human Antibodies™, AbZelectPRO™, ThioBridge™, and LabZient™ are designed to give your program the best chance of clinical and commercial success.

• EpiScreen® 2.0 — an extensive suite of bioinformatic and primary human cell-based assays for immunogenicity assessment to inform of potential safety and efficacy risks in the clinic.
• Composite Human Antibody™ — a platform used for designing safer, more effective, humanized antibodies.
• Composite Proteins™ — a deimmunization technology that designs safer and more effective therapeutic proteins, devoid of human T cell epitopes, to minimize potential immunogenicity in patients without compromising activity.
• AbZelectPRO™ — high-yielding cell line development (CLD) platform for accelerating the generation of production cell lines for manufacture of antibodies and recombinant proteins.
• ThioBridge™ — a next-generation conjugation linker technology proven to enhance ADC development by overcoming issues with existing technologies to improve stability, potency, and efficacy.
• LabZient™ — our analytical platform that combines predictive in-silico evaluation with laboratory methods to de-risk the application of platform analytical procedures and expedites the pathway to IND.